Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28282462 | 0.88 | ALDH1A1 (0.44) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL9044954 | 0.86 | MAPK13 (0.44) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL4249310 | 0.85 | ALDH1A1 (0.50) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL9050046 | 0.83 | TSHR (0.47) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL28051317 | 0.82 | BCAT2 (0.42) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL7093772 | 0.81 | BCAT2 (0.47) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL147847 | 0.80 | ALDH1A1 (0.69) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL10992096 | 0.79 | SIRT1 (0.46) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL9254902 | 0.79 | ALDH1A1 (0.56) | MAPTALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL4956421 | 0.79 | KMT2A (0.59) | MAPTALDH1A1TSHRTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102170882-A | Compositions and methods of treating amyloid disease | TREVENTIS CORP | 2011-08-31 | — | — | CN | claimed |
| CN-119613436-A | Boron nitrogen heterocyclic compound and application thereof in electrolyte | 欣旺达动力科技股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-109608407-B | Synthetic method of dibenzo seven-membered nitrogen-containing heterocyclic compound | 河北科技大学 | 2020-08-11 | — | — | CN | disclosed |
| CN-109608407-A | A kind of synthetic method of seven member heterocyclic ring containing nitrogen compound of dibenzo | 河北科技大学 | 2019-04-12 | — | — | CN | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
| CN-102170882-A | Compositions and methods of treating amyloid disease | TREVENTIS CORP | 2011-08-31 | — | — | CN | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | MAPT 2/4885ALDH1A1 2718/4885TSHR 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.